Europe Nucleic Acid Therapeutics Market

ID: MRFR/HC/11136-HCR
128 Pages
Vikita Thakur
Last Updated: April 06, 2026
Europe Nucleic Acid Therapeutics Market Research Report Information By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others), By Application (Monogenetic Disorders and Multi-genetic Disorders), By End User (Hospitals and Clinics and Academic and Research Institutes) – and Europe Market Forecast Till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Oncology
      2. 4.1.2 Genetic Disorders
      3. 4.1.3 Infectious Diseases
      4. 4.1.4 Cardiovascular Diseases
      5. 4.1.5 Neurological Disorders
    2. 4.2 Healthcare, BY Technology (USD Million)
      1. 4.2.1 RNA Interference
      2. 4.2.2 Antisense Oligonucleotides
      3. 4.2.3 CRISPR
      4. 4.2.4 Gene Therapy
      5. 4.2.5 DNA Vaccines
    3. 4.3 Healthcare, BY Route of Administration (USD Million)
      1. 4.3.1 Intravenous
      2. 4.3.2 Subcutaneous
      3. 4.3.3 Intramuscular
      4. 4.3.4 Oral
      5. 4.3.5 Topical
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sanofi (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 AstraZeneca (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 GSK (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 BioNTech (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 CureVac (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Genmab (DK)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 EUROPE MARKET ANALYSIS BY APPLICATION
    3. 6.3 EUROPE MARKET ANALYSIS BY TECHNOLOGY
    4. 6.4 EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF HEALTHCARE
    8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
    11. 6.11 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    12. 6.12 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    13. 6.13 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY TECHNOLOGY, 2026-2035 (USD Million)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Europe Europe Nucleic Acid Therapeutics Market Segmentation

Europe Nucleic Acid Therapeutics Market By Application (USD Million, 2026-2035)

  • Oncology
  • Genetic Disorders
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders

Europe Nucleic Acid Therapeutics Market By Technology (USD Million, 2026-2035)

  • RNA Interference
  • Antisense Oligonucleotides
  • CRISPR
  • Gene Therapy
  • DNA Vaccines

Europe Nucleic Acid Therapeutics Market By Route of Administration (USD Million, 2026-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Oral
  • Topical

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035